Alqam Mona L, Jones Brian C, Hitchcock Thomas M
Crown Laboratories Scientific Affairs Division Dallas Texas USA.
Crown Laboratories Chief Science Officer Dallas Texas USA.
Skin Health Dis. 2023 Jul 5;3(5):e264. doi: 10.1002/ski2.264. eCollection 2023 Oct.
Acne is an inflammatory disease of the pilosebaceous unit that occurs primarily in adolescents. There is no current ideal treatment for acne vulgaris, as many mainstay prescription treatment modalities can compromise the skin microbiome or have deleterious health effects. Further research is needed to investigate novel treatment modalities that account for the importance of the skin microbiome. Other developing treatment modalities for acne are still taking a similar mode of action as current treatments by trying to eliminate despite growing evidence that some strains may be symbiotic in nature. The perception that microneedling will exacerbate the disease state and trigger more acneic lesions via the spread of acne-associated microbes has hindered research investigating whether microneedling is a safe and effective treatment. This pilot clinical study challenges such perceptions by clinical assessment to determine if microneedling may produce beneficial treatment outcomes without disrupting critical skin structure or skin microbiome.
Test the safety and efficacy of microneedling as an effective treatment modality for acne vulgaris.
Subjects were split into two groups, one group received three treatments 4 weeks apart, and the second group received four treatments 2 weeks apart. Subjects received an acne assessment by an expert clinical grader at all clinical visits.
There was a statistically significant reduction in both non-inflammatory and inflammatory lesions at the 2-month follow-up compared to the baseline for Group 1. Group 1 and Group 2 saw a decline of 48.20% and 54.00% in non-inflammatory lesions and 57.97% and 36.67% in inflammatory lesions, respectively, at their last visit compared to baseline.
This study expands the utility of microneedling into a potential therapeutic modality for acne vulgaris. The data generated during the duration of this clinical study demonstrates that there is no scientific reason for microneedling to be contraindicated for acne. In this pilot, microneedling did not cause post-treatment complications and was seen to reduce acne lesions effectively. Thus, microneedling may have the potential to be a well-tolerated option for those suffering from acne, being a treatment that neither damages the sebaceous glands nor disrupts the skin microbiome.
痤疮是一种主要发生在青少年的毛囊皮脂腺单位的炎症性疾病。目前尚无针对寻常痤疮的理想治疗方法,因为许多主要的处方治疗方式可能会损害皮肤微生物群或对健康产生有害影响。需要进一步研究以探索考虑到皮肤微生物群重要性的新型治疗方式。痤疮的其他正在开发的治疗方式仍采用与当前治疗相似的作用模式,试图消除痤疮相关微生物,尽管越来越多的证据表明某些菌株可能本质上是共生的。认为微针治疗会通过痤疮相关微生物的传播加剧疾病状态并引发更多痤疮皮损的观念阻碍了关于微针治疗是否是一种安全有效治疗方法的研究。这项初步临床研究通过临床评估挑战了这种观念,以确定微针治疗是否可以在不破坏关键皮肤结构或皮肤微生物群的情况下产生有益的治疗效果。
测试微针治疗作为寻常痤疮有效治疗方式的安全性和有效性。
将受试者分为两组,一组每隔4周接受三次治疗,第二组每隔2周接受四次治疗。所有临床访视时,受试者均由专业临床评分员进行痤疮评估。
与第1组基线相比,在2个月随访时,非炎性和炎性皮损均有统计学意义的减少。与基线相比,第1组和第2组在最后一次访视时非炎性皮损分别下降了48.20%和54.00%,炎性皮损分别下降了57.97%和36.67%。
本研究将微针治疗的效用扩展为寻常痤疮的一种潜在治疗方式。在这项临床研究期间产生的数据表明,没有科学依据表明微针治疗对痤疮是禁忌的。在这项初步研究中,微针治疗未引起治疗后并发症,且能有效减少痤疮皮损。因此,对于痤疮患者而言,微针治疗可能是一种耐受性良好的选择,它既不会损害皮脂腺,也不会破坏皮肤微生物群。